We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Test Identifies Bacteria from Blood Culture

By LabMedica International staff writers
Posted on 01 Feb 2011
Print article
A molecular based diagnostic test is now available that will identify three different Gram-negative bacteria in less than 90 minutes from positive blood cultures.

The assay uses peptide nucleic acid (PNA) probes to target species-specific ribosomal ribonucleic acid (rRNA) in live bacteria and yeast coupled with highly sensitive and specific fluorescence in situ hybridization (FISH).

The GNR Traffic Light PNA FISH test is capable of simultaneously identifying Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa directly from positive blood cultures containing Gram-negative rods. The unique properties of the noncharged, peptide backbone of PNA probes enable the use of FISH assays in exceedingly complex sample matrixes, such as blood and blood cultures, and this in turn facilitates the development of very simple, yet very accurate tests that do not require the extensive sample preparation necessary for other nucleic acid technologies.

The assay is manufactured by AdvanDX, (Woburn, MA, USA) and has received 510(k) clearance from the US Food and Drug Administration (FDA; Silver Spring, MD, USA). The test is the latest addition to AdvanDx's easy-to-use, molecular-based PNA FISH diagnostics platform designed to provide rapid, therapy-guiding results that enable clinicians to provide early, effective therapy for patients with Gram-negative bloodstream infections (BSI).

The GNR Traffic Light PNA FISH assay will enable microbiology laboratories to identify and report E. coli, K. pneumoniae, and P. aeruginosa from positive blood cultures 24-48 hours earlier than traditional methods. The rapid results will provide clinicians a "head start" on selecting appropriate and effective therapy for patients with Gram-negative bloodstream infections, which studies show may improve clinical outcomes, reduce incidence of adverse events and shorten hospital length of stay.

Related Links:
AdvanDX
FDA

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.